LRP5 mutations are associated with osteoporosis, impaired glucose tolerance and hypercholesterolemia

被引：0
|
作者：
Saarinen, A. [1 ]
Saukkonen, T. [2 ]
Somer, M. [3 ]
Laine, C. M. [2 ]
Toiviainen-Salo, S. [4 ]
Lehesjoki, A. [1 ]
Makitie, O. [2 ]
机构：
[1] Univ Helsinki, Folkhalsan Inst Genet, Helsinki, Finland
[2] Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland
[3] Family Fed Finland, Helsinki, Finland
[4] Helsinki Univ Hosp, Helsinki Med Imaging Ctr, Helsinki, Finland
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2007年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S281
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [21] The lrp5 knockout zebrafish as a model to study osteoporosis
    Coucke, P. J.
    Bek, J.
    De Saffel, H.
    De Clercq, A.
    Boel, A.
    Willaert, A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 249 - 250
  • [22] LRP5 BIALLELIC MUTATIONS CAUSE A HIGHER INCIDENCE OF SEVERE PHENOTYPE COMPARED WITH LRP5 MONOALLELIC MUTATION
    Chen, Chunli
    Zhang, Xiang
    Peng, Xiaoyan
    Hu, Feng
    Cheng, Yizhe
    Zhao, Peiquan
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2022, 42 (10): : 1958 - 1964
  • [23] Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG)
    C M Laine
    B D Chung
    M Susic
    T Prescott
    O Semler
    T Fiskerstrand
    P D'Eufemia
    M Castori
    M Pekkinen
    E Sochett
    W G Cole
    C Netzer
    O Mäkitie
    European Journal of Human Genetics, 2011, 19 : 875 - 881
  • [24] LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders
    Levasseur, R
    Lacombe, D
    de Vernejoul, MC
    JOINT BONE SPINE, 2005, 72 (03) : 207 - 214
  • [25] Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG)
    Laine, C. M.
    Chung, B. D.
    Susic, M.
    Prescott, T.
    Semler, O.
    Fiskerstrand, T.
    D'Eufemia, P.
    Castori, M.
    Pekkinen, M.
    Sochett, E.
    Cole, W. G.
    Netzer, C.
    Makitie, O.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2011, 19 (08) : 875 - 881
  • [26] Atorvastatin attenuates Lrp5/Wnt-mediated atherosclerosis and osteoporosis in a mouse model of experimental hypercholesterolemia.
    Rajamannan, N. M.
    Subramaniam, M.
    Caira, F. C.
    Stock, S.
    Hefferan, T.
    Flores, A.
    Spelsberg, T. C.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (02) : S358 - S358
  • [27] Pseudogliomatous osteoporosis due to homozygous mutation of the LRP5 gene
    Ramon y Cajal Calvo, Juan
    Ortiz Gimenez, Ramon
    Zamora Lozano, Marta
    ANALES DE PEDIATRIA, 2022, 96 (05): : 461 - 462
  • [28] Osteoporosis-Pseudoglioma Syndrome: Three Novel Mutations in the LRP5 Gene and Response to Bisphosphonate Treatment
    Tuysuz, B.
    Bursali, A.
    Alp, Z.
    Suyugul, N.
    Laine, C. M.
    Makitie, O.
    HORMONE RESEARCH IN PAEDIATRICS, 2012, 77 (02): : 115 - 120
  • [29] LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST
    Semenov, Mikhail V.
    He, Xi
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (50) : 38276 - 38284
  • [30] Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity
    Korvala, Johanna
    Jueppner, Harald
    Makitie, Outi
    Sochett, Etienne
    Schnabel, Dirk
    Mora, Stefano
    Bartels, Cynthia F.
    Warman, Matthew L.
    Deraska, Donald
    Cole, William G.
    Hartikka, Heini
    Ala-Kokko, Leena
    Mannikko, Minna
    BMC MEDICAL GENETICS, 2012, 13
12345